JidduK schreef op 2 april 2019 11:55:
2 Incredibly Cheap Pharma Stocks to Buy Now - Apr 1, 2019 at 9:15AM
"Turning to the specifics, Wall Street has filgotinib's peak sales ranging from a low of $1.1 billion all the way up to a healthy $3.7 billion, and that's just for the drug's rheumatoid arthritis indication. Follow-on studies in psoriatic arthritis, ankylosing spondylitis (spinal arthritis), and Crohn's disease could tack on another $3 billion to this tally.
In all, this top biotech stock is far too cheap based on filgotinib's megablockbuster prospects -- a fact that the market will probably start to realize in the weeks ahead."
www.fool.com/investing/2019/04/01/2-i...